The dual PI3K/mTOR inhibitor NVP-bez235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Roper, Jatin ^a   Richardson, Michael P ^a   Wang, Wei Vivian ^a   Richard, Larissa Georgeon ^b   Chen, Wei ^a   Coffee, Erin M ^a   Sinnamon, Mark J ^a   Lee, Lydia ^a   Chen, Peng Chieh ^b   Bronson, Roderick T ^c   Martin, Eric S ^c   Hung, Kenneth E ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; IMIDAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TISSUE LEVEL; GENETIC ENGINEERING; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; PIK3CA GENE; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; CELL STRAIN HCT116; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE MUTANT; TUMOR CELL LINE; WESTERN BLOTTING;

MUS;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; HCT116 CELLS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; QUINOLINES; SIGNAL TRANSDUCTION;

EID: 80053169195     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025132     Document Type: Article

References (69)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Wolpin BM, Mayer RJ, (2008) Systemic treatment of colorectal cancer. Gastroenterology 134: 1296-1310.
3. Efeyan A, Sabatini DM, (2010) mTOR and cancer: many loops in one pathway. Current Opinion in Cell Biology 22: 169-176.
4. Zoncu R, Efeyan A, Sabatini DM, (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35.
5. Engelman JA, Luo J, Cantley LC, (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619.
6. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
7. Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573.
8. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, et al. (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7: 261-269.
9. Currie RA, Walker KS, Gray A, Deak M, Casamayor A, et al. (1999) Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J 337 (Pt 3): 575-583.
10. Fujishita T, Aoki M, Taketo MM, (2009) The role of mTORC1 pathway in intestinal tumorigenesis. Cell Cycle 8: 3684-3687.
11. Hung KE, Maricevich MA, Richard LG, Chen WY, Richardson MP, et al. (2010) Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci USA 107: 1565-1570.
12. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM, (2008) Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci USA 105: 13544-13549.
13. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, et al. (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26: 1603-1610.
14. Sturgill TW, Hall MN, (2009) Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha. ACS Chem Biol 4: 999-1015.
15. Cao P, Maira S-M, García-Echeverría C, Hedley DW, (2009) Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 100: 1267-1276.
16. Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, et al. (2010) Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 70: 8097-8107.
17. McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, et al. (2009) Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 69: 5835-5842.
18. Xu C-X, Zhao L, Yue P, Fang G, Tao H, et al. (2011) Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther 12 [Epub ahead of print].
19. Zitzmann K, Rüden J von, Brand S, Göke B, Lichtl J, et al. (2010) Compensatory activation of Akt in response to mTOR and Raf inhibitors- a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 295: 100-109.
20. Sunayama J, Matsuda K-I, Sato A, Tachibana K, Suzuki K, et al. (2010) Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells. Stem Cells 28: 1930-9.
21. Faber AC, Li D, Song Y, Liang M-C, Yeap BY, et al. (2009) Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 106: 19503-19508.
22. Sunayama J, Sato A, Matsuda K-I, Tachibana K, Suzuki K, et al. (2010) Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol 12: 1205-19.
23. Bhatt AP, Bhende PM, Sin S-H, Roy D, Dittmer DP, et al. (2010) Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 115: 4455-4463.
24. Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, et al. (2009) Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res 69: 7644-7652.
25. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, et al. (2010) Dual inhibition of PI3K and mTORC1/2 signalling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 16: 5424-35.
26. Santiskulvong C, Konecny GE, Fekete M, Chen K-YM, Karam A, et al. (2011) Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma. Clin Cancer Res 17: 2373-84.
27. Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, et al. (2010) Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 115: 559-569.
28. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356.
29. Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PMJ, et al. (2008) Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 68: 6598-6607.
30. Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D, (2009) Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer 8: 38.
31. Masuda M, Shimomura M, Kobayashi K, Kojima S, Nakatsura T, (2011) Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Oncol Rep [Epub ahead of print].
32. Maira S-M, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
33. Kong D, Dan S, Yamazaki K, Yamori T, (2010) Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. Eur J Cancer 46: 1111-1121.
34. Buonamici S, Williams J, Morrissey M, Wang A, Guo R, et al. (2010) Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2: 51ra70.
35. Lee M, Theodoropoulou M, Graw J, Roncaroli F, Zatelli MC, et al. (2011) Levels of p27 Sensitize to Dual PI3K/mTOR Inhibition. Mol Cancer Ther [Epub ahead of print] doi: 10.1158/1535-7163.MCT-11-0188.
36. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, et al. (2010) NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 16: 530-540.
37. Martin SK, Fitter S, Bong LF, Drew JJ, Gronthos S, et al. (2010) NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J Bone Miner Res 25: 2126-2137.
38. Serra V, Markman B, Scaltriti M, Eichhorn PJA, Valero V, et al. (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030.
39. Liu T-J, Koul D, LaFortune T, Tiao N, Shen RJ, et al. (2009) NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 8: 2204-2210.
40. Eichhorn PJA, Gili M, Scaltriti M, Serra V, Guzman M, et al. (2008) Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68: 9221-9230.
41. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, et al. (2009) Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 106: 22299-22304.
42. Marone R, Erhart D, Mertz AC, Bohnacker T, Schnell C, et al. (2009) Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res 7: 601-613.
43. Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, et al. (2011) Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer 10: 90.
44. Xu C-X, Li Y, Yue P, Owonikoko TK, Ramalingam SS, et al. (2011) The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo. PLoS ONE 6: e20899.
45. Herrera VA, Zeindl-Eberhart E, Jung A, Huber RM, Bergner A, (2011) The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines. Anticancer Res 31: 849-854.
46. Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B, (2010) The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 24: 1781-1784.
47. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, et al. (2010) The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 16: 3628-3638.
48. Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R, (2009) The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 315: 485-497.
49. Brünner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, et al. (2011) The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat 129: 387-400.
50. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira S-M, et al. (2009) The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 106: 268-273.
51. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, et al. (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120: 2858-2866.
52. Tanaka H, Yoshida M, Tanimura H, Fujii T, Sakata K, et al. (2011) The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations. Clinical Cancer Research 17: 3272-3281.
53. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, et al. (2011) Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer 117: 1399-1408.
54. Chang Q, Chen E, Hedley DW, (2009) Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. Cancer Biol Ther 8: 1893-1901.
55. Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, et al. (2007) Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120: 1803-1810.
56. Guertin DA, Sabatini DM, (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
57. Bunney TD, Katan M, (2010) Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 10: 342-352.
58. Liu P, Cheng H, Roberts TM, Zhao JJ, (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644.
59. Chalhoub N, Baker SJ, (2009) PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4: 127-150.
60. Bhaskar PT, Hay N, (2007) The Two TORCs and Akt. Developmental Cell 12: 487-502.
61. Ihle NT, Lemos R, Wipf P, Yacoub A, Mitchell C, et al. (2009) Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance. Cancer Research 69: 143-150.
62. Guo X-N, Rajput A, Rose R, Hauser J, Beko A, et al. (2007) Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. Cancer Res 67: 5851-5858.
63. Martin-Fernandez C, Bales J, Hodgkinson C, Welman A, Welham MJ, et al. (2009) Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs. Mol Cancer Res 7: 955-965.
64. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, et al. (2011) PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. Mol Cancer Ther 10: 558-565.
65. Sharpless NE, Depinho RA, (2006) The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5: 741-754.
66. Taketo MM, Edelmann W, (2009) Mouse models of colon cancer. Gastroenterology 136: 780-798.
67. Mallon RG, Feldberg LR, Lucas J, Chaudhary I, Dehnhardt C, et al. (2011) Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor. Clin Cancer Res 17: 3193-203.
68. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, et al. (2011) mTORC1 and mTORC2 regulate EMT, motility and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 71 (9): 3246-56.
69. Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, et al. (2009) Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 8: 742-753.